Medy-Tox Inc.

A086900

KR7086900008

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 20/05/2024 am IST			5-day change	1st Jan Change
1,31,600 ^KRW	-1.28%		-3.94%	-45.39%

21/03	Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
05/01	South Korean Shares Close Marginally Lower on North Korea's Artillery Shells Firing	MT

Tranche Update on Medy-Tox Inc.'s Equity Buyback Plan announced on February 18, 2022.

April 05, 2022 at 11:29 am IST

From February 18, 2022 to March 31, 2022, the company has repurchased 43,821 shares, representing 0.72% for KRW 5,450.18 million. With this, the company has completed the repurchase of 43,821 shares, representing 0.72% for KRW 5,450.18 million under the buyback announced on February 18, 2022.

Latest news about Medy-Tox Inc.

Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
South Korean Shares Close Marginally Lower on North Korea's Artillery Shells Firing	05/01	MT
Medy Tox Establishes Subsidiary Luvantas in California	05/01	MT
Medytox, Inc. Announces the Formation of Luvantas Subsidiary	03/01	CI
Medytox, Inc. Announces Executive Appointments in Luvantas, Inc	03/01	CI
Medy-Tox Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
Medy-Tox Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
AEON Biopharma, Inc. completed the acquisition of Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.	21/23/21	CI
Medy-Tox Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	21/23/21	CI
AEON Biopharma, Inc. entered into a definitive business combination agreement to acquire Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.	13/22/13	CI
Medy-Tox Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
Tranche Update on Medy-Tox Inc.'s Equity Buyback Plan announced on August 17, 2022.	27/22/27	CI
Medy-Tox Inc.'s Equity Buyback announced on August 17, 2022, has closed with 41,771 shares, representing 0.70% for KRW 5,084.38 million.	22/22/22	CI
Medy-Tox Inc.(KOSDAQ:A086900) dropped from FTSE All-World Index	19/22/19	CI
Medy-Tox Inc. announces an Equity Buyback for 41,771 shares.	17/22/17	CI
Medy-Tox Inc. authorizes a Buyback Plan.	17/22/17	CI
Medy-Tox Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
Tranche Update on Medy-Tox Inc.'s Equity Buyback Plan announced on June 7, 2022.	08/22/08	CI
Medy-Tox Inc.'s Equity Buyback announced on June 7, 2022, has closed with 39,777 shares, representing 0.66% for KRW 4,574.17 million.	06/22/06	CI
Medy-Tox Inc. announces an Equity Buyback for 39,777 shares.	07/22/07	CI
Medy-Tox Inc. authorizes a Buyback Plan.	07/22/07	CI
Medy-Tox Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/22/16	CI
Tranche Update on Medy-Tox Inc.'s Equity Buyback Plan announced on February 18, 2022.	05/22/05	CI
Medy-Tox Inc.'s Equity Buyback announced on February 18, 2022, has closed with 43,821 shares, representing 0.72% for KRW 5,450.18 million.	31/22/31	CI

Chart Medy-Tox Inc.

Duration

Period

More charts

Company Profile

Medy Tox Inc is a Korea-based company engaged in the development, manufacture and marketing of biopharmaceuticals. The Companyâs main product is type A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. Its products are also used in chin plastic surgeries. The Company provides its products under the brand names of Medytoxin, Neurox, Siax, and Neuramis. In addition, the Company develops and sells medical devices such as injectors under the brand names of Neurajet, Neurafen and others. The Company also engages in technology transfer. The Company distributes its products in domestic and overseas markets such as Japan, China, Russia and Europe.

Sector

Pharmaceuticals

Calendar

09/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Medy-Tox Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,31,600 KRW

Average target price

2,96,000 KRW

Spread / Average Target

+124.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
MEDY-TOX INC.	-45.39%	663M
CSL LIMITED	-3.05%	90.45B
SAMSUNG BIOLOGICS CO.,LTD.	+3.95%	41.45B
BIOGEN INC.	-10.43%	33.57B
UCB	+60.58%	25.73B
BIOMARIN PHARMACEUTICAL INC.	-20.71%	14.73B
INCYTE CORPORATION	-8.89%	12.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.46%	11.7B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.05%	11.44B
SWEDISH ORPHAN BIOVITRUM AB	+5.17%	8.79B

Biopharmaceuticals

Medy-Tox Inc.

Equities

A086900

KR7086900008

Pharmaceuticals

Tranche Update on Medy-Tox Inc.'s Equity Buyback Plan announced on February 18, 2022.

Latest news about Medy-Tox Inc.

Chart Medy-Tox Inc.

Company Profile

Income Statement Evolution

Ratings for Medy-Tox Inc.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Biopharmaceuticals